GSK plc vs Plug Power Inc — how do they compare? GSK plc trades at $51.15 (market cap $104.15B), while Plug Power Inc trades at $2.22 (market cap $2.94B). The key difference: GSK plc is far larger — about 35.4× Plug Power Inc's market cap, and GSK plc pays a 3.48% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| GSK | PLUG | |
|---|---|---|
Market Cap | $104.15B | $2.94B |
Sector | Health | Industrials |
52-Week High | $61.18 | $4.14 |
52-Week Low | $37.71 | $1.41 |
Enterprise Value | $124.56B | $3.73B |
Dividend Yield | 3.48% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.96, up 1.51% today, with strong technical momentum showing bullish moving averages and neutral oscillators. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $1.36 beating estimates by 7%. Recent FDA approval for Jideytro lung cancer therapy and a $2.52 billion cost-saving initiative support growth prospects. Valuation metrics remain reasonable with P/E of 16.69 and EV/EBITDA of 9.68.
GSK presents a balanced investment case with solid fundamentals and pipeline progress offset by margin pressure risks. The company's 29.73% ROE and consistent dividend payments provide shareholder value, while competitive pressures and patent expirations require careful monitoring. Analyst consensus leans Hold (55%) with 31% Buy ratings, suggesting cautious optimism for the pharmaceutical giant's transformation under new leadership.
Plug Power (PLUG) trades at $2.18, up 5.31% with a bearish technical signal despite recent earnings beat. The company shows improving operational metrics with reduced cash usage and margin improvements, though it remains unprofitable with negative gross margins of -25.66%. Management targets positive EBITDA by Q4 2026 while navigating significant liquidity challenges through asset sales and financing activities.
While analyst consensus leans bullish with a $2.22 price target, PLUG faces substantial execution risks amid persistent losses and cash burn. The stock offers speculative upside if management delivers on profitability targets, but investors face elevated risk from the company's negative cash flow and competitive hydrogen market pressures.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →